Notice: Undefined index: HTTP_REFERER in /home/stemookh/ on line 583
Metabolic Syndrome Has a Negative Impact on Cost Utility Following Spine Surgery. – Back Pain Doctor Harley Street

Metabolic Syndrome Has a Negative Impact on Cost Utility Following Spine Surgery.


Investigate the differences in spine surgery cost for metabolic syndrome patients.


Included: Patients ≥18, undergoing fusion. Patients were divided into cervical, thoracic, and lumbar groups based on their upper instrumented vertebrae (UIV). Metabolic syndrome patients (MetS) included: BMI >30, DM, dyslipidemia, and HTN. Propensity score matching for invasiveness between Non-MetS and MetS used to assess cost differences. Total surgery costs for MetS and non-MetS ASD patients were compared. QALYs and cost per QALY for UIV groups were calculated.


312 invasiveness matched surgeries met inclusion criteria. Baseline demographics and surgical details: age 57.7 ± 14.5, 54% female, BMI 31.1 ± 6.6, 17% anterior approach, 70% posterior approach, 13% combined approach, 3.8 ± 4.1 levels fused. The average costs of surgery between MetS and non-Mets patients was $60,579.30 vs. $52,053.23 (p<0.05). When costs were compared between UIV groups, MetS patients had higher cervical and thoracic surgery costs ($23,203.43 vs $19,153.43, $75,230.05 vs. $65,746.16, all p<0.05) and lower lumbar costs ($31,775.64 vs. $42,643.37, p<0.05). However, the average cost per QALY at 1Y was $639,069.32 for MetS patients and $425,840.30 for non-Mets patients (p<0.05). At life expectancy, the cost per QALY was $45,456.83 vs. $26,026.84 (p<0.05).


When matched by invasiveness, metabolic syndrome patients had an average 16.4% higher surgery costs, 50% higher costs per quality adjusted life years at 1 year, and 75% higher cost per quality adjusted life years at life expectancy. Further research is needed on the possible utility of reducing comorbidities in preoperative patients.

Share on facebook
Share on twitter
Share on linkedin
Share on vk
Share on pinterest
Close Menu